Although our understanding of the association between breast implants and anaplastic large-cell lymphoma (ALCL) has increased since the first published case report in 1997,1 questions about this unique clinicopathological entity still outnumber the answers. What causes breast implant-associated anaplastic large-cell lymphoma (BIA-ALCL)? Who is at risk? How great is the risk? What is the optimal treatment?